- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Temecula, California • Minneapolis, Minnesota • Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 1,666
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes (DM)
- Interventions
- Not listed
- Lead sponsor
- 4YouandMe
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Closed Loop with Pramlintide
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Type 1 Diabetes
- Interventions
- Exenatide
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 56 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes
- Interventions
- Observational
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 13 Years to 26 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Type I Diabetes
- Interventions
- DICE
- Behavioral
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Gan & Lee Insulin Glargine Injection, Lantus®
- Biological
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more
- Conditions
- Diabetes (Insulin-requiring, Type 1 or Type 2)
- Interventions
- Undermyfork Care App, Usual Care
- Device · Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypoglycemia
- Interventions
- Naltrexone High Dose, Naltrexone Low Dose
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo for dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more
- Conditions
- Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure
- Interventions
- Fluoxetine, Placebo control
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pressure Ulcer, Foot Ulcer, Diabetic
- Interventions
- Santyl, Standard Care
- Biological · Other
- Lead sponsor
- Smith & Nephew, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Usual care, Collaborative care model (CoCM)
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type I, Diabetes Mellitus, Insulin-Dependent, 1, Type 1 Diabetes Mellitus, Insulin-Dependent Diabetes Mellitus 1, IDDM
- Interventions
- Imatinib Mesylate, Placebo (For imatinib mesylate)
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas
- Drug · Device
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 1 Diabetes, Dawn Phenomenon
- Interventions
- Lantus (glargine)
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Experimental prospective single arm evaluating the Medtronic Duo Extended Set
- Device
- Lead sponsor
- Atlanta Diabetes Associates
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Non-Insulin-Dependent Diabetes Mellitus
- Interventions
- pioglitazone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Belmont, Massachusetts
- Conditions
- Type 1 Diabetes
- Interventions
- Pump suspension algorithm
- Device
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 3 Years to 14 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Stanford, California • Aurora, Colorado
- Conditions
- Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
- Interventions
- Adipose tissue biopsy
- Procedure
- Lead sponsor
- The University of Texas Medical Branch, Galveston
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Sleep Promotion
- Behavioral
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Experimental hypoglycemia
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 1 Diabetes
- Interventions
- Formoterol, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 1 Diabetes
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 2 Years to 26 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado